0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Slow Resolution of Clinically Active Trachoma Following Successful Mass Antibiotic Treatments FREE

Jeremy D. Keenan, MD, MPH; Takele Lakew, MD, MPH; Wondu Alemayehu, MD, MPH; Muluken Melese, MD, MPH; Jenafir I. House, MPH; Nisha R. Acharya, MD, MS; Travis C. Porco, PhD, MPH; Bruce D. Gaynor, MD; Thomas M. Lietman, MD
[+] Author Affiliations

Author Affiliations: F. I. Proctor Foundation (Drs Keenan, Acharya, Porco, Gaynor, and Lietman and Ms House), Departments of Ophthalmology (Drs Keenan, Acharya, Porco, Gaynor, and Lietman) and Epidemiology and Biostatistics (Drs Porco and Lietman), and Institute for Global Health (Dr Lietman), University of California, San Francisco; and ORBIS International, Addis Ababa, Ethiopia (Drs Lakew, Alemayehu, and Melese).


Arch Ophthalmol. 2011;129(4):512-526. doi:10.1001/archophthalmol.2011.46.
Text Size: A A A
Published online

Trachoma, caused by infection with ocular strains of chlamydia, is the leading infectious cause of blindness worldwide. The World Health Organization recommends that in districts where the prevalence of clinically active trachoma exceeds 10% in children aged 1 to 9 years, communities should receive 3 annual mass antibiotic distributions followed by clinical reassessment; any communities with persistent trachoma should continue receiving annual mass antibiotic treatments until the prevalence of clinically active trachoma in children aged 1 to 9 years falls below 5%.1

Although trachoma treatment decisions are based on the prevalence of clinically active trachoma, it is unclear how quickly the clinical signs of trachoma resolve once infection has been cleared, especially in areas with severe trachoma. We recently performed a series of cluster-randomized clinical trials for trachoma in an area of Ethiopia with hyperendemic trachoma. In these trials, infection was brought to a low level in 24 villages randomized to receive mass azithromycin treatments every 6 months. This provided an opportunity to determine the rate of resolution of the clinical signs of trachoma given little to no chlamydial reinfection.

Twenty-four randomly selected villages received mass azithromycin treatment every 6 months for 18 months.2,3 In these villages, we monitored the prevalence of ocular chlamydia and clinically active trachoma in all children aged 1 to 5 years 2 months after baseline and then every 6 months after baseline for 24 months. Monitoring preceded mass antibiotic treatment at each of the biannual visits. Ocular chlamydial prevalence was assessed using maximum likelihood estimations from pooled chlamydial polymerase chain reaction (Amplicor; Roche Diagnostics, Branchburg, New Jersey) as described previously.2,3 Clinically active trachoma was defined as follicular trachoma and/or intense inflammatory trachoma according to the World Health Organization's simplified grading system.1 Clinical examiners were trained and validated against gold-standard examiners as described previously.4

The primary outcome was the resolution rate of clinically active trachoma at the village level. We used a generalized estimating equation to predict the log prevalence of clinically active trachoma during biannual monitoring visits, using time and the log baseline prevalence of clinically active trachoma as fixed effects, village as a random effect, a first-order autoregressive correlation structure, and the Huber-White sandwich estimate of variance. Use of the log-transformed outcome was decided a priori and was supported by plots of the residual vs fitted values. Analyses were performed with Stata version 10.0 statistical software (StataCorp LP, College Station, Texas).

The mean prevalence of ocular chlamydial infection in children before the baseline mass azithromycin treatment was 52.9% (95% confidence interval, 44.2%-61.3%) (Figure).4 Mass azithromycin distribution subsequently occurred at months 0, 6, 12, and 18. The mean prevalence of ocular chlamydia in children during posttreatment biannual monitoring visits was 5.1% (95% confidence interval, 3.6%-6.6%). During these 24 months, the prevalence of clinically active trachoma decreased by 33.3% (95% confidence interval, 28.6%-38.0%) per year as estimated from the generalized estimating equation (Figure).

Place holder to copy figure label and caption
Figure.

Prevalence of ocular chlamydial infection and clinically active trachoma in 24 Ethiopian villages. At months 0, 6, 12, and 18, mass azithromycin treatments were distributed subsequent to monitoring. Each solid gray line represents an individual village; the solid black line represents the summary of all 24 villages (assessed by generalized estimating equation, assuming the mean baseline prevalence of clinically active trachoma).

Graphic Jump Location

In a hyperendemic area, repeated biannual mass antibiotic treatments reduced the level of ocular chlamydial infection in children to a low level. The prevalence of the clinical signs of active trachoma declined at a much slower rate of 33.3% per year. This rate of resolution is somewhat lower than that reported elsewhere.5,6 However, prior reports have been conducted in fewer villages, with less severe trachoma. In contrast, this study was conducted in many villages in an area with severe trachoma and specifically included the variation among villages in the analysis. Furthermore, our analysis assessed the prevalence of clinically active trachoma in a village as opposed to its presence in an individual. A village-level analysis is most useful for trachoma program managers, who make treatment decisions based on the prevalence of trachoma in a village. Our findings suggest that in areas with hyperendemic trachoma treated through mass distribution of azithromycin, the signs of active trachoma can be expected to resolve slowly, even if antibiotic distributions are quite successful in reducing the prevalence of ocular chlamydia.

Correspondence: Dr Keenan, F. I. Proctor Foundation and Department of Ophthalmology, University of California, San Francisco, 95 Kirkham St, San Francisco, CA 94143 (jeremy.keenan@ucsf.edu).

Financial Disclosure: None reported.

Funding/Support: This work was supported by grants K23 EY019071 and U10 EY016214 from the National Institutes of Health, the Heed Ophthalmic Foundation, the International Trachoma Initiative, the Bernard Osher Foundation, That Man May See, the Peierls Foundation, the Bodri Foundation, the Harper Inglis Trust, the South Asia Research Fund, and Research to Prevent Blindness.

Additional Contributions: The Ethiopian Ministry of Health and many health care professionals, including Tadesse Kebede, Berhanu Fikre, Mifta Shifa, MPH, and Tadesse Birru, helped us organize and implement our fieldwork in Ethiopia.

Solomon  AWZondervan  MKuper  HBuchan  JCMabey  DCWFoster  A Trachoma Control: A Guide for Programme Managers.  Geneva, Switzerland World Health Organization2006;
Melese  MAlemayehu  WLakew  T  et al.  Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008;299 (7) 778- 784
PubMed Link to Article
Lakew  THouse  JHong  KC  et al.  Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl Trop Dis 2009;3 (2) e376
PubMed Link to Article
Keenan  JDLakew  TAlemayehu  W  et al.  Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma. Am J Trop Med Hyg 2010;82 (3) 482- 487
PubMed Link to Article
Bailey  RLArullendran  PWhittle  HCMabey  DC Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993;342 (8869) 453- 456
PubMed Link to Article
Fraser-Hurt  NBailey  RLCousens  SMabey  DFaal  HMabey  DC Efficacy of oral azithromycin vs topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ 2001;79 (7) 632- 640
PubMed

Figures

Place holder to copy figure label and caption
Figure.

Prevalence of ocular chlamydial infection and clinically active trachoma in 24 Ethiopian villages. At months 0, 6, 12, and 18, mass azithromycin treatments were distributed subsequent to monitoring. Each solid gray line represents an individual village; the solid black line represents the summary of all 24 villages (assessed by generalized estimating equation, assuming the mean baseline prevalence of clinically active trachoma).

Graphic Jump Location

Tables

References

Solomon  AWZondervan  MKuper  HBuchan  JCMabey  DCWFoster  A Trachoma Control: A Guide for Programme Managers.  Geneva, Switzerland World Health Organization2006;
Melese  MAlemayehu  WLakew  T  et al.  Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008;299 (7) 778- 784
PubMed Link to Article
Lakew  THouse  JHong  KC  et al.  Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl Trop Dis 2009;3 (2) e376
PubMed Link to Article
Keenan  JDLakew  TAlemayehu  W  et al.  Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma. Am J Trop Med Hyg 2010;82 (3) 482- 487
PubMed Link to Article
Bailey  RLArullendran  PWhittle  HCMabey  DC Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993;342 (8869) 453- 456
PubMed Link to Article
Fraser-Hurt  NBailey  RLCousens  SMabey  DFaal  HMabey  DC Efficacy of oral azithromycin vs topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ 2001;79 (7) 632- 640
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Trachoma. Lancet Published online Jul 16, 2014.;
JAMAevidence.com

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario